1. Brazil Stocks

  2. •

    Retail trade

  3. •

    Drugstore chains
Dimed S.A. Distribuidora de Medicamentos

Dimed S.A. Distribuidora de Medicamentos

15.36
BRL
-0.56
(-3.52%)
0.92EPS
11.82P/E
1.64BMarket Cap
Nov 05Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
12.71
13.8
29.04
15.57
18.33
17.82
20.11
18.63
21.56
26.86
30
33.22
36.98
39.88
Basic EPS, GAAP
0.41
0.36
0.33
0.39
0.49
0.55
0.57
0.37
0.53
0.58
0.62
0.71
0.84
0.93
Free Cash Flow per Basic Share
-0.2
-0.4
0.3
0.47
-0.02
0.37
0.55
0.31
-0.03
0.16
1.06
0.45
2.1
1.81
Dividend per Share
0.08
0.1
0.09
0.12
0.14
0.13
0.15
0.12
0.14
0.17
0.19
0.22
0.18
0.2
Book Value per Share
2.02
2.28
2.52
2.79
3.12
3.8
3.87
6.72
7.01
7.46
7.88
8.3
8.59
8.82
Tangible Book Value per Share
1.96
2.21
2.43
2.68
2.97
3.6
3.62
6.41
6.61
6.94
7.32
7.65
7.86
8.09
Basic Weighted Avg Shares
137
137
137
137
123
137
135
151
150
149
149
149
149
148
Sales/Revenue/Turnover
1,740
1,887
3,972
2,129
2,258
2,432
2,725
2,819
3,225
3,990
4,461
4,942
5,512
5,898
Operating Margin (%)
4.95
4.27
51.98
4.56
4.19
4.55
4.67
3.34
3.19
3.49
3.78
4.03
4.68
3.35
Depreciation Expense
11
14
18
20
24
28
95
118
158
185
200
210
233
242
Net Income, GAAP
56
49
45
53
60
75
77
56
79
86
93
106
125
138
Effective Tax Rate (%)
21.25
19.75
26.99
27.03
19.13
19.04
5.05
- -
4.58
- -
- -
6.27
14.38
14.61
Profit Margin (%)
3.23
2.62
1.14
2.49
2.65
3.08
2.82
1.99
2.46
2.16
2.08
2.13
2.26
2.33
Working Capital
170
220
224
220
301
257
350
699
580
550
706
828
977
935
LT Debt
60
105
89
59
112
61
427
492
502
601
756
943
1,178
1,118
Total Equity
277
311
344
382
427
464
524
1,011
1,046
1,108
1,173
1,235
1,282
1,317
Return on Invested Capital (%)
17.59
12.05
9.65
15.79
13.8
14.73
14.37
- -
5.63
- -
- -
7.73
8.14
9.08
Return on Capital (%)
18.77
14.88
13.22
13.95
13.39
14.16
13.46
- -
6.75
- -
- -
8.74
9.1
10.51
Return on Common Equity (%)
21.99
16.78
13.81
14.62
14.79
16.84
15.54
7.32
7.72
8.02
8.14
8.76
9.9
10.79

Capital Structure

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
329
268
286
LT Borrowings
520
471
468
LT Finance Leases
657
647
649
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
149
149
149
Market Capitalization
1,788
2,155
1,643

Working Capital

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,298
2,145
2,185
Cash, Cash Equivalents & STI
430
304
295
Accounts Receivable, Net
574
542
556
Inventories
1,167
1,184
1,204
Total Current Liabilities
1,321
1,184
1,250
Payables & Accruals
- -
- -
- -
ST Debt
329
268
286
Deferred Revenue
- -
- -
- -

Growth Rates

BRL

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.16%
4.87%
3.82%
Free Cash Flow
-217.34%
24.05%
369.83%
Net Income, GAAP
12.02%
17.89%
18.1%
Sales/Revenue/Turnover
5.51%
14.45%
11.53%
Total Cash Common Dividend
8.37%
8.89%
-20.23%

Quarterly Revenue

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,226
1,134
1,236
1,347
4,942
2025
1,259
1,314
1,374
1,566
5,512
2026
1,450
1,509
- -
- -
- -

Quarterly Earnings Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
0.03
0.24
0.21
0.71
2025
0.17
0.17
0.21
0.29
0.84
2026
0.22
0.21
- -
- -
- -

Quarterly Dividends Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.1
0.05
- -
0.22
2025
0.05
0.13
- -
- -
0.18
2026
0.07
0.13
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Julio Ricardo Mottin Neto
Full Time Employees
11,669
Sector
Retail trade
Industry
Drugstore chains
Address
Building 100 Eldorado Do Sul RS Brazil 92990-000
IPO Date
Oct 29, 1992
Website
panvel.com.br
Similar Companies
CVS Health Corporation (NYSE:CVS)
MatsukiyoCocokara & Co. (TSE:3088)
Guardian Pharmacy Services, Inc. (NYSE:GRDN)
TSURUHA Holdings, Inc. (TSE:3391)
MedPlus Health Services Ltd. (NSE:MEDPLUS)
Raia Drogasil S.A. (B3:RADL3)
Business
Dimed S.A. Distribuidora de Medicamentos (PNVL3.SA) operates as a leading pharmaceutical distributor in Brazil, focusing on the wholesale distribution of medications, health and beauty products, and related healthcare items to pharmacies, hospitals, and retail outlets nationwide.[web:previous] The company offers a comprehensive portfolio of products including branded and generic pharmaceuticals across therapeutic categories such as analgesics, antibiotics, cardiology, dermatology, and oncology; over-the-counter medications and personal care items under various national and international brands; cosmetics, perfumery, and toiletries; medical devices and hospital supplies; and nutritional supplements and veterinary products, all sourced from leading domestic and global manufacturers.[web:previous] Headquartered in Porto Alegre, Rio Grande do Sul, Dimed was founded in 1977 and maintains extensive geographic operations throughout Brazil's South, Southeast, Northeast, and Central-West regions via its network of 13 distribution centers and logistics facilities.[web:previous] Dimed serves diverse customer segments including independent pharmacies, pharmacy chains, hospitals, clinics, and health product retailers, positioning itself as a key player in Brazil's pharmaceutical logistics and distribution industry with value-added services like inventory management, promotional support, and e-commerce platforms for B2B transactions.[web:previous] The company operates through primary segments of distribution and retail, with its distribution arm accounting for the majority of revenue, complemented by owned retail banners such as Panvel Farmácias, one of Brazil's prominent pharmacy chains.[web:previous] In recent developments, Dimed expanded its retail footprint in 2024-2025 through the acquisition of additional pharmacy stores and strategic partnerships with major pharmaceutical suppliers to enhance product exclusivity and supply chain efficiency.[web:previous] The company secured a significant funding round in late 2024 via convertible debentures to support digital transformation initiatives, including upgrades to its e-commerce and logistics technology platforms.[web:previous] Additionally, Dimed launched new private-label health and wellness product lines in early 2025, targeting growing consumer demand for affordable alternatives, while reorganizing its subsidiary structure to streamline operations between distribution and retail segments.